Please use this identifier to cite or link to this item:
Title: How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Authors: Fazekas, Franz
Bajenaru, Ovidiu
Berger, Thomas
Hojs Fabjan, Tanja
Ledinek, Alenka Horvat
Jakab, Gábor
Komoly, Samuel
Kobys, Tetiana
Kraus, Jörg
Kurca, Egon
Kyriakides, Theodoros
Lisý, Lubomír
Milanov, Ivan
Nehrych, Tetyana
Moskovko, Sergii
Panayiotou, Panayiotis
Jazbec, Saša Šega
Sokolova, Larysa
Taláb, Radomír
Traykov, Latchezar
Turcáni, Peter
Vass, Karl
Vella, Norbert
Voloshyná, Nataliya
Havrdová, Eva
Keywords: Multiple sclerosis -- Case studies
Multiple sclerosis -- Treatment
Issue Date: 2013
Publisher: Frontiers Research Foundation
Citation: Fazekas, F., Bajenaru, O., Berger, T., Hojs Fabjan, T., Horvat Ledinek, A., Jakab, G., ... & Kyriakides, T. (2013). How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?. Frontiers in Neurology, 4(10), 1-14.
Abstract: Multiple sclerosis (MS) is a neurological disorder characterized by inflammatory demyelination and neurodegeneration in the central nervous system. Until recently, disease-modifying treatment was based on agents requiring parenteral delivery, thus limiting long-term compliance. Basic treatments such as beta-interferon provide only moderate efficacy, and although therapies for second-line treatment and highly active MS are more effective, they are associated with potentially severe side effects. Fingolimod (Gilenya®) is the first oral treatment of MS and has recently been approved as single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis (RRMS) for adult patients with high disease activity despite basic treatment (beta-interferon) and for treatment-naïve patients with rapidly evolving severe RRMS. At a scientific meeting that took place in Vienna on November 18th, 2011, experts from ten Central and Eastern European countries discussed the clinical benefits and potential risks of fingolimod for MS, suggested how the new therapy fits within the current treatment algorithm and provided expert opinion for the selection and management of patients.
Appears in Collections:Scholarly Works - FacM&SMed

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.